All Stories

  1. Structural Insights into the Iodothyronine Deiodinase 2 Catalytic Core and Deiodinase Catalysis and Dimerization
  2. Identifying novel DIO1 inhibitors to modulate hepatic T3 availability in context of non-alcoholic fatty liver disease
  3. Identification of Human TRIAC Transmembrane Transporters
  4. Hyperthyroidism-driven bone loss depends on BMP receptor Bmpr1a expression in osteoblasts
  5. Screening for endocrine disrupting chemicals inhibiting monocarboxylate 8 (MCT8) transporter facilitated thyroid hormone transport using a modified nonradioactive assay
  6. Low thyroxine serves as an upstream regulator of ecophysiological adaptations in Ansell’s mole-rats
  7. Endocrine disrupting chemicals are a threat to hormone health: a commentary on behalf of the ESE
  8. Response to Fitzgerald et al. re: “Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status”
  9. Strong associations of serum selenoprotein P with all-cause mortality and mortality due to cancer, cardiovascular, respiratory and gastrointestinal diseases in older German adults
  10. Endocrine disruptors and thyroid function
  11. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status
  12. Clinical Interpretation of Thyroid Tests: Considerations for Reference Intervals
  13. Hepatic Energy Metabolism under the Local Control of the Thyroid Hormone System
  14. Comparative analysis of thyroid hormone systems in rodents with subterranean lifestyle
  15. Selenium, Iodine and Iron–Essential Trace Elements for Thyroid Hormone Synthesis and Metabolism
  16. The ETA–ESE statement on the European Chemicals Agency opinion on iodine as an endocrine disruptor
  17. Seizures, ataxia and parvalbumin-expressing interneurons respond to selenium supply in Selenop-deficient mice
  18. Deiodinases control local cellular and systemic thyroid hormone availability
  19. Human cerebral organoids as in vitro platform to assess thyroid hormone system disrupting chemicals
  20. 3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?
  21. Changes in Thyroid Metabolites after Liothyronine Administration: A Secondary Analysis of Two Clinical Trials That Incorporated Pharmacokinetic Data
  22. 3,5-T2 - An Endogenous Thyroid Hormone Metabolite As Promising Lead Substance in Anti-Steatotic Drug Development?
  23. Great impact in low quantities - thyroid hormones, trace elements and endocrine disruptors
  24. Tentative Application of a Streamlined Protocol to Determine Organ-Specific Regulations of Deiodinase 1 and Dehalogenase Activities as Readouts of the Hypothalamus-Pituitary-Thyroid-Periphery-Axis
  25. 100 YEARS OF VITAMIN D: Light and health: a century after the therapeutic use of UV light and vitamin D, hormones advanced medical care
  26. Perinatal exposure to the thyroperoxidase inhibitors methimazole and amitrole perturbs thyroid hormone system signaling and alters motor activity in rat offspring
  27. Age-dependent response to T4 overtreatment and recovery on systemic and organ level
  28. Thyroid hormone system disrupting chemicals
  29. Testing for heterotopia formation in rats after developmental exposure to selected in vitro inhibitors of thyroperoxidase
  30. Comparative Analysis of the Effects of Long-Term 3,5-diiodothyronine Treatment on the Murine Hepatic Proteome and Transcriptome Under Conditions of Normal Diet and High-Fat Diet
  31. Identification of iodothyronine deiodinase 2 inhibitors among FDA-approved drug library using high throughput screening
  32. Goodbye and farewell to Endocrine Connections!
  33. Obesity and Pregnancy. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015-081, June 2019)
  34. Selenium in Endocrinology—Selenoprotein-Related Diseases, Population Studies, and Epidemiological Evidence
  35. Adversity Considerations for Thyroid Follicular Cell Hypertrophy and Hyperplasia in Nonclinical Toxicity Studies: Results From the 6th ESTP International Expert Workshop
  36. Disruption of BMP Signaling Prevents Hyperthyroidism‐Induced Bone Loss in Male Mice
  37. CD5L Constitutes a Novel Biomarker for Integrated Hepatic Thyroid Hormone Action
  38. Mass Spectrometry-Based Determination of Thyroid Hormones and Their Metabolites in Endocrine Diagnostics and Biomedical Research – Implications for Human Serum Diagnostics
  39. Endocrine, Metabolic and Pharmacological Effects of Thyronamines (TAM), Thyroacetic Acids (TA) and Thyroid Hormone Metabolites (THM) – Evidence from in vitro, Cellular, Experimental Animal and Human ...
  40. Removing Critical Gaps in Chemical Test Methods by Developing New Assays for the Identification of Thyroid Hormone System-Disrupting Chemicals—The ATHENA Project
  41. Lack of the Thyroid Hormone Transporter Mct8 in Osteoblast and Osteoclast Progenitors Increases Trabecular Bone in Male Mice
  42. 3,5-T2—A Janus-Faced Thyroid Hormone Metabolite Exerts Both Canonical T3-Mimetic Endocrine and Intracrine Hepatic Action
  43. A Thyroid Hormone-Independent Molecular Fingerprint of 3,5-Diiodothyronine Suggests a Strong Relationship with Coffee Metabolism in Humans
  44. A combined LC-MS/MS and LC-MS3 multi-method for the quantification of iodothyronines in human blood serum
  45. The isoflavones genistein and daidzein increase hepatic concentration of thyroid hormones and affect cholesterol metabolism in middle-aged male rats
  46. Aging Alters Phenotypic Traits of Thyroid Dysfunction in Male Mice With Divergent Effects on Complex Systems but Preserved Thyroid Hormone Action in Target Organs
  47. The Role of Dickkopf-1 in Thyroid Hormone–Induced Changes of Bone Remodeling in Male Mice
  48. 3-Iodothyronamine—A Thyroid Hormone Metabolite With Distinct Target Profiles and Mode of Action
  49. In Memoriam: Lewis E. Braverman (1929–2019)
  50. The Colorful Diversity of Thyroid Hormone Metabolites
  51. Endocrine Disruptors and Thyroid Function
  52. The Effect of High Dose Isoflavone Supplementation on Serum Reverse T3 in Euthyroid Men With Type 2 Diabetes and Post-menopausal Women
  53. Vascular Endothelial Growth Factor (VEGF) Induced Downstream Responses to Transient Receptor Potential Vanilloid 1 (TRPV1) and 3-Iodothyronamine (3-T1AM) in Human Corneal Keratocytes
  54. TRPM8 Activation via 3-Iodothyronamine Blunts VEGF-Induced Transactivation of TRPV1 in Human Uveal Melanoma Cells
  55. Association Between 3-Iodothyronamine (T1am) Concentrations and Left Ventricular Function in Chronic Heart Failure
  56. Effects of isoflavones on breast tissue and the thyroid hormone system in humans: a comprehensive safety evaluation
  57. Proteome analysis of 3,5-T2-treated primary mouse hepatocytes
  58. Genistein Increase Thyroid Hormone and 7 alpha-hydroxycholesterol concentrations in the liver of middle-aged male rats
  59. A thyroid hormone-independent molecular fingerprint of 3,5-diiodothyronine suggests a strong relation with coffee metabolism in humans
  60. Micronutrient status assessment in humans: Current methods of analysis and future trends
  61. Canonical TSH Regulation of Cathepsin-Mediated Thyroglobulin Processing in the Thyroid Gland of Male Mice Requires Taar1 Expression
  62. Thyroid Hormones and Derivatives: Endogenous Thyroid Hormones and Their Targets
  63. Relaxin-2 connecting peptide (pro-RLX2) levels in second trimester serum samples to predict preeclampsia
  64. 3-Iodothyronamine reduces insulin secretion in vitro via a mitochondrial mechanism
  65. Thyroid Hormone Metabolism
  66. Restoration of type 1 iodothyronine deiodinase expression in renal cancer cells downregulates oncoproteins and affects key metabolic pathways as well as anti-oxidative system
  67. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo
  68. BMPs as new insulin sensitizers: enhanced glucose uptake in mature 3T3-L1 adipocytes via PPARγ and GLUT4 upregulation
  69. In vivo Effects of Repeated Thyronamine Administration in Male C57BL/6J Mice
  70. Sex-specific phenotypes of hyperthyroidism and hypothyroidism in aged mice
  71. Editorial: Get inspired - Lessons learned from evolution of thyroid hormone signaling in developmental processes
  72. Avoiding the pitfalls when quantifying thyroid hormones and their metabolites using mass spectrometric methods: The role of quality assurance
  73. A validated LC-MS/MS method for cellular thyroid hormone metabolism: Uptake and turnover of mono-iodinated thyroid hormone metabolites by PCCL3 thyrocytes
  74. Quantification of Relaxin-2 Connecting Peptide (Pro-RLX2) in Human Blood Samples
  75. Sclerostin Blockade and Zoledronic Acid Improve Bone Mass and Strength in Male Mice With Exogenous Hyperthyroidism
  76. Aminoglycoside-driven biosynthesis of selenium-deficient Selenoprotein P
  77. Treatment with thyroid hormone metabolite 3,5-T2 alters cholesterol and sex steroid metabolism in mouse liver
  78. Igniting stage two in Endocrine Connections
  79. Sex-specific and inter-individual differences in biomarkers of selenium status identified by a calibrated ELISA for selenoprotein P
  80. Molecular features of the L-type amino acid transporter 2 determine different import and export profiles for thyroid hormones and amino acids
  81. 3-Iodothyronamine Decreases Expression of Genes Involved in Iodide Metabolism in Mouse Thyroids and Inhibits Iodide Uptake in PCCL3 Thyrocytes
  82. Thyroid hormone status defines brown adipose tissue activity and browning of white adipose tissues in mice
  83. A Nonradioactive DEHAL Assay for Testing Substrates, Inhibitors, and Monitoring Endogenous Activity
  84. Circulating 3-T1AM and 3,5-T2 in Critically Ill Patients: A Cross-Sectional Observational Study
  85. Thyronamines and Derivatives: Physiological Relevance, Pharmacological Actions, and Future Research Directions
  86. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease
  87. Selenoprotein Gene Nomenclature
  88. Factors impacting the aminoglycoside-induced UGA stop codon readthrough in selenoprotein translation
  89. Sex-specific phenotypes of hyperthyroidism and hypothyroidism in mice
  90. Efficacy of protocols for induction of chronic hyperthyroidism in male and female mice
  91. High Variability of Insulin Sensitivity in Closely Related Obese Mouse Inbred Strains
  92. Minireview: Insights Into the Structural and Molecular Consequences of the TSH-β Mutation C105Vfs114X
  93. Few Amino Acid Exchanges Expand the Substrate Spectrum of Monocarboxylate Transporter 10*
  94. Thyroid hormone and its metabolites in relation to quality of life in patients treated for differentiated thyroid cancer
  95. 3-T1AM signaling in the rat thyrocyte cell line PCCL3
  96. Circulating 3-T1AM and 3,5-T2 in critically ill patients: a cross-sectional observational study
  97. Faculty Opinions recommendation of Mutation in human selenocysteine transfer RNA selectively disrupts selenoprotein synthesis.
  98. Impact of Endocrine Disruptor Policies and Regulations
  99. Silychristin, a Flavonolignan Derived From the Milk Thistle, Is a Potent Inhibitor of the Thyroid Hormone Transporter MCT8
  100. Exposure to Thyroid-Disrupting Chemicals: A Transatlantic Call for Action
  101. High levels of thyroid-stimulating hormone are associated with aortic wall thickness in the general population
  102. 3-Iodothyronamine increases transient receptor potential melastatin channel 8 (TRPM8) activity in immortalized human corneal epithelial cells
  103. A bioactive thyroid hormone metabolite alters hepatic metabolism
  104. Differential Modulation of Adrenergic Receptor Signaling by Octopamine, Tyramine, Phenylethylamine, and 3-Iodothyronamine
  105. Selenium and Endocrine Tissues
  106. Selenoprotein P and Selenium Distribution in Mammals
  107. Testosterone and estradiol treatments differently affect pituitary-thyroid axis and liver deiodinase 1 activity in orchidectomized middle-aged rats
  108. Biosynthesis of 3-Iodothyronamine From T4in Murine Intestinal Tissue
  109. Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1
  110. Chronic Kidney Disease Distinctly Affects Relationship Between Selenoprotein P Status and Serum Thyroid Hormone Parameters
  111. Selenium and the thyroid
  112. An Improved Nonradioactive Screening Method Identifies Genistein and Xanthohumol as Potent Inhibitors of Iodothyronine Deiodinases
  113. The Effects of Thyroid Hormones on Gene Expression of Acyl-Coenzyme A Thioesterases in Adipose Tissue and Liver of Mice
  114. A Nonradioactive Uptake Assay for Rapid Analysis of Thyroid Hormone Transporter Function
  115. Trace Amine-Associated Receptor 1 Localization at the Apical Plasma Membrane Domain of Fisher Rat Thyroid Epithelial Cells Is Confined to Cilia
  116. 3-iodothyronamine differentially modulates α-2A-adrenergic receptor-mediated signaling
  117. Structural Insights Into Thyroid Hormone Transport Mechanisms of the L-Type Amino Acid Transporter 2
  118. 3,5-T2 might play a crucial role in the rodent heart
  119. Abnormal circulating thyroid hormone levels in MCT8-deficiency are not caused by increased hepatic conversion through type i-deiodinase
  120. Effects of repeated 3-T1AM treatment on thyrocytes in mice
  121. Effects of the thyroid hormone metabolite 3,5-T2 on murine heart tissue and the cardiomyocyte cell line H9C2
  122. Establishment of a non-isotopic activity assay for thyroid hormone transporters
  123. Influence of thyroid hormones on brown adipose tissue activity and browning of white adipose tissues in mice
  124. New G protein coupled receptor targets for 3-iodotyronamine
  125. Phenotypic and molecular characterization of age-dependent thyroid hormone action in mice
  126. Quantitative analysis of thyroid hormone metabolites in cell culture samples using LC-MS/MS
  127. Towards the intestinal biosynthesis of 3-iodothyronamine
  128. Inverse Agonistic Action of 3-Iodothyronamine at the Human Trace Amine-Associated Receptor 5
  129. Establishment and characterization of a new ELISA for selenoprotein P
  130. Lokalisation und Verteilung von Selenoprotein P im humanen Gehirn
  131. Thyronamine induces TRPM8 channel activation in human conjunctival epithelial cells
  132. Translating Pharmacological Findings from Hypothyroid Rodents to Euthyroid Humans: Is There a Functional Role of Endogenous 3,5-T2?
  133. Nonthyroidal Illness Syndrome in Cardiac Illness Involves Elevated Concentrations of 3,5-Diiodothyronine and Correlates with Atrial Remodeling
  134. 3,5-Diiodo-L-Thyronine (3,5-T2) Exerts Thyromimetic Effects on Hypothalamus-Pituitary-Thyroid Axis, Body Composition, and Energy Metabolism in Male Diet-Induced Obese Mice
  135. Differences in Mouse Hepatic Thyroid Hormone Transporter Expression with Age and Hyperthyroidism
  136. Establishment of an Effective Radioiodide Thyroid Ablation Protocol in Mice
  137. High T3, Low T4 Serum Levels in Mct8 Deficiency Are Not Caused by Increased Hepatic Conversion through Type I Deiodinase
  138. Involvement of the L-Type Amino Acid Transporter Lat2 in the Transport of 3,3′-Diiodothyronine across the Plasma Membrane
  139. Quantitative Analysis of Thyroid Hormone Metabolites in Cell Culture Samples Using LC-MS/MS
  140. Serum Thyrotropin Concentrations Are Not Associated with the Ankle-Brachial Index: Results from Three Population-Based Studies
  141. The Multitarget Ligand 3-Iodothyronamine Modulates β-Adrenergic Receptor 2 Signaling
  142. Urine Metabolomics by 1H-NMR Spectroscopy Indicates Associations between Serum 3,5-T2 Concentrations and Intermediary Metabolism in Euthyroid Humans
  143. Analysis of Human TAAR8 and Murine Taar8b Mediated Signaling Pathways and Expression Profile
  144. High Serum Thyrotropin Levels Are Associated with Retinal Arteriolar Narrowing in the General Population
  145. Selenium status in patients with autoimmune and non-autoimmune thyroid diseases from four European countries
  146. Detection of 3,5-Diiodothyronine in Sera of Patients with Altered Thyroid Status Using a New Monoclonal Antibody-Based Chemiluminescence Immunoassay
  147. Hepatic metabolite profiles in mice with a suboptimal selenium status
  148. Thyroxine: beneficial for mutated TRα receptors thwarting thyroid hormone action?
  149. Crystal structure of mammalian selenocysteine-dependent iodothyronine deiodinase suggests a peroxiredoxin-like catalytic mechanism
  150. Soy isoflavones interfere with thyroid hormone homeostasis in orchidectomized middle-aged rats
  151. Transport of Thyroid Hormone in Brain
  152. Screening assays on inhibitors, modulators and substrates of deiodinase and dehalogenase activities
  153. The mouse Leydig cell line MLTC-1 prefers L-thyroxine over 3,3',5-triiodo-L-thyronine in transport across plasma membrane and shows steroidogenesis response to thyroid hormone treatment
  154. Aspects of 3-iodothyronamine (3T1AM) induced signaling by human and mouse trace amine-associated receptor 5 (TAAR5)
  155. Evidence for thyromimetic action of 3,5-T2 in diet-induced obese mice
  156. Functional and metabolic responses of thyrocytes to 3-Iodothyronamine (3-T1AM)
  157. Role of 3,5-diiodothyronine in chronic kidney disease
  158. Supplementieren oder nicht? Das Spurenelement Selen
  159. Hormone des Hypothalamus und der Hypophyse
  160. Schilddrüsenhormone – Zentrale Regulatoren von Entwicklung, Wachstum, Grundumsatz, Stoffwechsel und Zelldifferenzierung
  161. Steroidhormone – Produkte von Nebennierenrinde und Keimdrüsen
  162. Wachstumshormon und Prolactin
  163. Selenium and the thyroid
  164. Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies
  165. Function of thyroid hormone transporters in the central nervous system
  166. Evaluation of the Association between Persistent Organic Pollutants (POPs) and Diabetes in Epidemiological Studies: A National Toxicology Program Workshop Review
  167. Thyroid Hormone Disruptors and In Vitro Screening
  168. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study,,
  169. Serum selenium is low in newly diagnosed Graves’ disease: a population-based study
  170. Establishment of a competitive chemiluminescence immunoassay to detect 3,5-T2 in human serum
  171. Strong associations of 25-hydroxyvitamin D levels with all-cause, cardiovascular, cancer and respiratory disease mortality in a large cohort study
  172. Thyroid hormone transporters during testicular development in rodents
  173. Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study
  174. Autoantibodies to the IGF1 Receptor in Graves' Orbitopathy
  175. Se- and S-Based Thiouracil and Methimazole Analogues Exert Different Inhibitory Mechanisms on Type 1 and Type 2 Deiodinases
  176. Bone Turnover and Bone Mineral Density Are Independently Related to Selenium Status in Healthy Euthyroid Postmenopausal Women
  177. Standardization of Misleading Immunoassay Based 25-Hydroxyvitamin D Levels with Liquid Chromatography Tandem-Mass Spectrometry in a Large Cohort Study
  178. Thyroid Function Is Maintained Despite Increased Oxidative Stress in Mice Lacking Selenoprotein Biosynthesis in Thyroid Epithelial Cells
  179. Orchidectomy of middle-aged rats decreases liver deiodinase 1 and pituitary deiodinase 2 activity
  180. LC–MS/MS detection of thyroid hormone metabolites in tissue samples
  181. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia
  182. Identification of Iopanoic Acid as Substrate of Type 1 Deiodinase by a Novel Nonradioactive Iodide-Release Assay
  183. Selen
  184. Plasma Bile Acids Are Associated with Energy Expenditure and Thyroid Function in Humans
  185. Does the aromatic l-amino acid decarboxylase contribute to thyronamine biosynthesis?
  186. Tyrosine Kinase Inhibitors Noncompetitively Inhibit MCT8-Mediated Iodothyronine Transport
  187. Selenium
  188. Differential Modulation of Beta-Adrenergic Receptor Signaling by Trace Amine-Associated Receptor 1 Agonists
  189. Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture
  190. Monocarboxylate transporter 8 deficiency: altered thyroid morphology and persistent high triiodothyronine/thyroxine ratio after thyroidectomy
  191. Aminoaciduria, but normal thyroid hormone levels and signalling, in mice lacking the amino acid and thyroid hormone transporter Slc7a8
  192. Faculty Opinions recommendation of Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial.
  193. Copeptin and Peroxiredoxin-4 Independently Predict Mortality in Patients With Nonspecific Complaints Presenting to the Emergency Department
  194. Environmental factors
  195. Faculty Opinions recommendation of Selenium and the course of mild Graves' orbitopathy.
  196. Evidence for Extrathyroidal Formation of 3-Iodothyronamine in Humans as Provided by a Novel Monoclonal Antibody-Based Chemiluminescent Serum Immunoassay
  197. Circulating Levels of Peroxiredoxin 4 as a Novel Biomarker of Oxidative Stress in Patients with Sepsis: Erratum
  198. Circulating Levels of Peroxiredoxin 4 as a Novel Biomarker of Oxidative Stress in Patients with Sepsis
  199. Faculty Opinions recommendation of The effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk markers in patients with subclinical hypothyroidism: a randomized, double-blind, crossover study.
  200. Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency
  201. Thyronamines—Past, Present, and Future
  202. Insights into molecular properties of the human monocarboxylate transporter 8 by combining functional with structural information
  203. Selenium Transport in Mammals: Selenoprotein P and Its Receptors
  204. Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells
  205. Faculty Opinions recommendation of Tissue distribution and cardiac metabolism of 3-iodothyronamine.
  206. Report on the 4th International FESTEM Symposium on “Recent advances in trace element research: From experiments to nutritional and clinical applications in humans” (Saint Petersburg, Russia, June 09–12th, 2010)
  207. Mutation of megalin leads to urinary loss of selenoprotein P and selenium deficiency in serum, liver, kidneys and brain
  208. Immunoluminometric assay for quantification of peroxiredoxin 4 in human serum
  209. Essential Molecular Determinants for Thyroid Hormone Transport and First Structural Implications for Monocarboxylate Transporter 8
  210. Faculty Opinions recommendation of A coherent organization of differentiation proteins is required to maintain an appropriate thyroid function in the Pendred thyroid.
  211. Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma
  212. Xanthohumol, a prenylated chalcone from hops, modulates hepatic expression of genes involved in thyroid hormone distribution and metabolism
  213. Effect of mutations of the human serpin protein corticosteroid-binding globulin on cortisol-binding, thermal and protease sensitivity
  214. Synthese, Stoffwechsel und Diagnostik der Schilddrüsenhormone
  215. Midregional Proenkephalin A and N-terminal Protachykinin A are decreased in the cerebrospinal fluid of patients with dementia disorders and acute neuroinflammation
  216. Faculty Opinions recommendation of Thyrostimulin, but not thyroid-stimulating hormone (TSH), acts as a paracrine regulator to activate the TSH receptor in mammalian ovary.
  217. Secretion of Antioxidant Peroxiredoxin 4 in Response to Oxidative Stress
  218. Increased risk of thyroid pathology in patients with thyroid hemiagenesis: results of a large cohort case–control study
  219. Selenium and thyroid
  220. Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration
  221. Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients
  222. Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependent
  223. Neuronal 3′,3,5-Triiodothyronine (T3) Uptake and Behavioral Phenotype of Mice Deficient inMct8, the Neuronal T3Transporter Mutated in Allan–Herndon–Dudley Syndrome
  224. Expression of Iodothyronine Deiodinase in Cultured Thyroid Cells
  225. Thyroid hormone deiodination in target tissues — a regulatory role for the trace dement selenium?
  226. Interference of Endocrine Disrupters with Thyroid Hormone Receptor–Dependent Transactivation
  227. Selenium Supplementation Fails to Correct the Selenoprotein Synthesis Defect in Subjects with SBP2 Gene Mutations
  228. Down‐regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice
  229. Faculty Opinions recommendation of Thyroid hormones directly alter human hair follicle functions: anagen prolongation and stimulation of both hair matrix keratinocyte proliferation and hair pigmentation.
  230. Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines
  231. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health
  232. V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis
  233. Development of a validated liquid chromatography/tandem mass spectrometry method for the distinction of thyronine and thyronamine constitutional isomers and for the identification of new deiodinase substrates
  234. Peroxides and Peroxide-Degrading Enzymes in the Thyroid
  235. Faculty Opinions recommendation of A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity.
  236. Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid
  237. Faculty Opinions recommendation of Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats.
  238. Thyronamines Are Isozyme-Specific Substrates of Deiodinases
  239. Thyroid disrupting chemicals: mechanisms and mixtures
  240. Environment and endocrinology: The case of thyroidology
  241. New assay for the measurement of selenoprotein P as a sepsis biomarker from serum
  242. Hepatic selenoprotein P (SePP) expression restores selenium transport and prevents infertility and motor-incoordination in Sepp-knockout mice
  243. Welcome to Thyroid Research
  244. Phthalates: metabolism and exposure
  245. Endocrine Disruptors and the Thyroid Gland—A Combined in Vitro and in Vivo Analysis of Potential New Biomarkers
  246. The KiSS‐1/GPR54 system: putative target for endocrine disruption of reproduction at hypothalamic–pituitary unit?
  247. Selenoproteins of the thyroid gland: expression, localization and possible function of glutathione peroxidase 3
  248. Selenoproteins – biochemistry and clinical relevance
  249. Effects of a 5-day treatment with the UV-filter octyl-methoxycinnamate (OMC) on the function of the hypothalamo-pituitary–thyroid function in rats
  250. Procalcitonin is elevated in the cerebrospinal fluid of patients with dementia and acute neuroinflammation
  251. The Ultraviolet Filter Benzophenone 2 Interferes with the Thyroid Hormone Axis in Rats and Is a Potentin VitroInhibitor of Human Recombinant Thyroid Peroxidase
  252. Thyroid hormone transporters in health and disease: advances in thyroid hormone deiodination
  253. Neuronal and ependymal expression of selenoprotein P in the human brain
  254. Hypothalamisch-hypophysäres System und Zielgewebe
  255. Selenium-Dependent Pre- and Posttranscriptional Mechanisms Are Responsible for Sexual Dimorphic Expression of Selenoproteins in Murine Tissues
  256. Selenium and goiter prevalence in borderline iodine sufficiency
  257. Effects of isoflavonoids and other plant-derived compounds on the hypothalamus–pituitary–thyroid hormone axis
  258. Contributions of cytokines to nonthyroidal illness
  259. Proenkephalin A 119–159, a stable proenkephalin A precursor fragment identified in human circulation
  260. Genistein and other soya isoflavones are potent ligands for transthyretin in serum and cerebrospinal fluid
  261. Distinct roles for neuronal selenoproteins in cerebellar development
  262. Synthesis and Metabolism of Thyroid Hormones Is Preferentially Maintained in Selenium-Deficient Transgenic Mice
  263. Selenium and goiter prevalence in borderline iodine sufficiency
  264. Nutritional Genomics
  265. Molekularmedizinische Grundlagen von para- und autokrinen Regulationsstörungen
  266. Selen – Selenoproteine – Selenmangel – Selenvergiftung
  267. Selenium, the Thyroid, and the Endocrine System
  268. Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice
  269. Letter re: Id1 Gene Expression in Hyperplastic and Neoplastic Thyroid Tissues
  270. Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels, but not for thyroid hormone-dependent gene expression
  271. Purkinje cell degeneration and loss of cerebellar interneurons during development of mice lacking neuronal selenoprotein biosynthesis
  272. Selenoprotein biosynthesis – importance of structural elements in the 3‘-untranslated region
  273. Xanthohumol stimulates iodide uptake in rat thyroid-derived FRTL-5 cells
  274. Selenium and the Control of Thyroid Hormone Metabolism
  275. Free-flow isoelectric focusing of proteins remaining in cell fragments following sonication of thyroid carcinoma cells
  276. Selenoprotein Expression in Hürthle Cell Carcinomas and in the Human Hürthle Cell Carcinoma Line XTC.UC1
  277. Developmentally regulated thyroid hormone distributor proteins in marsupials, a reptile, and fish
  278. Tissue-specific growth-defects upon Selenium-deficiency
  279. Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply
  280. Endocrine active compounds affect thyrotropin and thyroid hormone levels in serum as well as endpoints of thyroid hormone action in liver, heart and kidney
  281. Guard Your Master: Thyroid Hormone Receptors Protect Their Gland of Origin from Thyroid Cancer
  282. CD82, and CD63 in thyroid cancer.
  283. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation
  284. Interleukin-18, a proinflammatory cytokine, contributes to the pathogenesis of non-thyroidal illness mainly via the central part of the hypothalamus-pituitary-thyroid axis
  285. Selenium in biology and medicine—further progress and increasing interest
  286. Selenium and selenoproteins in mammals: extraordinary, essential, enigmatic
  287. 55th Mosbach Colloquium: How nutrients influence gene activity
  288. Selenium and brain function: a poorly recognized liaison
  289. Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses
  290. Efficient selenium transfer from mother to offspring in selenoprotein-P-deficient mice enables dose-dependent rescue of phenotypes associated with selenium deficiency
  291. Contribution of Interleukin-12 to the Pathogenesis of Non-thyroidal Illness
  292. Expression of CD97 and CD55 in human medullary thyroid carcinomas
  293. Thyroid Hormone Metabolism
  294. Exciting new perspectives and further necessity for selenium research in Europe
  295. Expression Profiling and Genetic Alterations of the Selenoproteins GI-GPx and SePP in Colorectal Carcinogenesis
  296. Selenium Supplementation Enhances Low Selenium Levels and Stimulates Glutathione Peroxidase Activity in Peripheral Blood and Distal Colon Mucosa in Past and Present Carriers of Colon Adenomas
  297. Glutathione peroxidase isoforms as part of the local antioxidative defense system in normal and Barrett's esophagus
  298. Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues
  299. The Impact of Iron and Selenium Deficiencies on Iodine and Thyroid Metabolism: Biochemistry and Relevance to Public Health
  300. A complex DNA-repeat structure within the Selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency
  301. Expression of telomerase genes in thyroid carcinoma
  302. Expression of 5'-deiodinase enzymes in normal pituitaries and in various human pituitary adenomas
  303. Thyroid hormone receptors and type I iodothyronine 5′-deiodinase activity of human thyroid toxic adenomas and benign cold nodules
  304. Proinflammatory cytokines inhibit the expression and function of human type I 5'-deiodinase in HepG2 hepatocarcinoma cells
  305. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study
  306. The promoter of the human sodium/iodide-symporter gene responds to retinoic acid
  307. Stoffwechselerkrankungen
  308. Innentitel
  309. Iodothyronine Deiodinases
  310. Spectral karyotype analysis of colon cancer cell lines of the tumor suppressor and mutator pathway
  311. Vitamine, Spurenelemente und Mineralstoffe
  312. Identification of an element within the promoter of human selenoprotein P responsive to transforming growth factor‐β
  313. Modulation of selenoprotein P expression by TGF‐β1 is mediated by Smad proteins
  314. The deiodinase family: selenoenzymes regulating thyroid hormone availability and action
  315. Effects of proinflammatory cytokines on anterior pituitary 5'-deiodinase type I and type II
  316. Innovative strategies for the treatment of thyroid cancer
  317. Inverse mRNA Expression of the Selenocysteine-Containing Proteins GI-GPx and SeP in Colorectal Adenomas Compared With Adjacent Normal Mucosa
  318. Retinoic Acid Redifferentiation Therapy for Thyroid Cancer
  319. Loss of selenoprotein P (SeP) expression in colorectal adenomas: Implications for carcinogenesis
  320. Characterization of Barrett's and regenerative squamous mucosa by muc1 and muc2 mRNA expression
  321. Analysis of the selenoprotein P promoter in colorectal carcinogenesis
  322. Thyroid Hormone Metabolism and Action in the Brain and Pituitary
  323. Thyroid Hormone Metabolism and Action in the Brain and Pituitary
  324. Selenium in Biology: Facts and Medical Perspectives
  325. The influence of the cytokines Il‐1β and INFγ on the expression of selenoproteins in the human hepatocarcinoma cell line HepG2
  326. Increased I-131 Uptake in Local Recurrence and Distant Metastases After Second Treatment With Retinoic Acid
  327. Transforming growth factor‐β1 inhibits expression of selenoprotein P in cultured human liver cells
  328. Expression of selenoproteins in monocytes and macrophages — Implications for the immune system
  329. Local activation and inactivation of thyroid hormones: the deiodinase family
  330. The trace element selenium and the thyroid gland
  331. Type 1 deiodinase is stimulated by iodothyronines and involved in thyroid hormone metabolism in human somatomammotroph GX cells
  332. Regulation of CD97 Protein in Thyroid Carcinoma1
  333. The selenoprotein thioredoxin reductase is expressed in peripheral blood monocytes and THP1 human myeloid leukemia cells - regulation by 1,25-dihydroxyvitamin D3and selenite
  334. Selensupplementation durch Selenhefe und Natriumselenit: Analyse des Selenstatus sowie Risiken des Mangels und der Intoxikation. Selenium Supplementation by Selenium Yeast and Sodium Selenite: Analysis of the Selenium Status as well as Risks of Deficie...
  335. Reverse Transcriptase-Polymerase Chain Reaction Analysis of Thyrocyte-Relevant Genes in Fine-Needle Aspiration Biopsies of the Human Thyroid
  336. Wie kommt Jod in die Schilddr�se?
  337. Redifferentiation Therapy with Retinoids: Therapeutic Option for Advanced Follicular and Papillary Thyroid Carcinoma
  338. Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues
  339. Functional retinoid and thyroid hormone receptors in human thyroid‐carcinoma cell lines and tissues
  340. Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid Cells
  341. European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel
  342. The Human Analog of Murine Cystein Rich Protein 16 Is a 1α,25-Dihydroxyvitamin D3Responsive Immediate Early Gene in Human Fetal Osteoblasts: Regulation by Cytokines, Growth Factors, and Serum1
  343. Selenoproteins Are Expressed in Fetal Human Osteoblast-like Cells
  344. Expression pattern of gastrointestinal selenoproteins— targets for selenium supplementation
  345. Identification by differential display PCR of the selenoprotein thioredoxin reductase as a 1α,25(OH)_2‐vitamin D_3‐responsive gene in human osteoblasts — regulation by selenite
  346. Discussion
  347. Cloning and Characterization of the Human Selenoprotein P Promoter
  348. Retinoic Acid Increases Sodium/Iodide Symporter mRNA Levels in Human Thyroid Cancer Cell Lines and Suppresses Expression of Functional Symporter in Nontransformed FRTL-5 Rat Thyroid Cells
  349. Selenoproteine im Knochen, Gastrointestinaltrakt und in der Schilddrüse des Menschen
  350. 3,5-Diiodo-l-Thyronine Stimulates Type 1 5′Deiodinase Activity in Rat Anterior Pituitariesin Vivoand in Reaggregate Cultures and GH3 Cellsin Vitro1
  351. Consensus statement on lung cancer
  352. 3,5-Diiodo-L-Thyronine Stimulates Type 1 5'Deiodinase Activity in Rat Anterior Pituitaries in Vivo and in Reaggregate Cultures and GH3 Cells in Vitro
  353. The Promoter of the Human Type I 5′‐Deiodinase Gene — Mapping of the Transcription Start Site and Identification of a DR+4 Thyroid‐Hormone‐Responsive Element
  354. Structure of the Human Type I Iodothyronine 5′-Deiodinase Gene and Localization to Chromosome 1p32–p33
  355. Local estradiol metabolism in osteoblast- and osteoclast-like cells
  356. Local Estradiol Metabolism in Osteoblast- and Osteoclast-like Cells
  357. Different Tissue Distribution, Elimination, and Kinetics of Thyroxine and Its Conformational Analog, the Synthetic Flavonoid EMD 49209 in the Rat1
  358. Different Tissue Distribution, Elimination, and Kinetics of Thyroxine and Its Conformational Analog, the Synthetic Flavonoid EMD 49209 in the Rat
  359. Thyroid Carcinoma: Interrelationships Between Local Thyroid Hormone Metabolism by the Type I 5′-Deiodinase and the Expression of Thyroid Hormone Receptors and Other Thyroid-Specific (De-)differentiation Markers
  360. Selected Novel Flavones Inhibit the DNA Binding or the DNA Religation Step of Eukaryotic Topoisomerase I
  361. Binding of Thyroxine to Pig Transthyretin, its cDNA Structure, and Other Properties
  362. Binding of Thyroxine to Pig Transthyretin, its cDNA Structure, and Other Properties
  363. Expression and regulation of aromatase cytochrome P450 in THP 1 human myeloid leukaemia cells
  364. Differential selenium-dependent expression of type I 5′-deiodinase and glutathione peroxidase in the porcine epithelial kidney cell line LLC-PK1
  365. Rapid stimulation of type I 5′-deiodinase in rat pituitaries by 3,3′,5-triiodo-l-thyronine
  366. Cloning of a cDNA encoding an ectoenzyme that degrades thyrotropin-releasing hormone.
  367. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines.
  368. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines
  369. Topoisomerase I Inhibition Enhances Vitamin D-Responsive Expression of the Receptor for Lipopolysaccharide Binding Protein CD 14
  370. Thyroxine transport to the brain: role of protein synthesis by the choroid plexus.
  371. Selective labelling and inactivation of creatine kinase isoenzymes by the thyroid hormone derivative N-bromoacetyl-3,3′,5-tri-iodo-l-thyronine
  372. Selenium-dependent regulation of type I 5′-deiodinase expression
  373. Early adaptation of thyrotropin and thyroglobulin secretion to experimentally decreased iodine supply in man
  374. Thyroxine (T4) transport and distribution in rats treated with EMD 21388, a synthetic flavonoid that displaces T4 from transthyretin.
  375. Thyroxine (T4) transport and distribution in rats treated with EMD 21388, a synthetic flavonoid that displaces T4 from transthyretin
  376. Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain.
  377. Human thyrotropin receptor gene: Expression in thyroid tumors and correlation to markers of thyroid differentiation and dedifferentiation
  378. Localization of type I iodothyronine 5'-deiodinase to the basolateral plasma membrane in renal cortical epithelial cells
  379. Identification of type I iodothyronine 5′-deiodinase as a selenoenzyme
  380. Flavonoid Administration Immediately Displaces Thyroxine (T4) from Serum Transthyretin, Increases Serum Free T4, and Decreases Serum Thyrotropin in the Rat*
  381. 5′-Deiodination in Rat Hepatocytes: Effects of Specific Flavonoid Inhibitors*
  382. Effect of Biological Alterations of Type I 5'Deiodinase Activity on Affinity Labeled Membrane Proteins in Rat Liver and Kidney*
  383. Thyroid hormone effect on rat heart mitochondrial proteins and affinity labeling with N‐bromoacetyl‐3,3′,5‐triiodo‐L‐thyronine Lack of direct effect on the adenine nucleotide translocase
  384. Rapid Effects of the Flavonoid EMD 21388 on Serum Thyroid Hormone Binding and Thyrotropin Regulation in the Rat*
  385. Affinity-labelling of T4-5′-deiodinase and serum T4-binding proteins
  386. Circadian and Pulsatile Thyrotropin Secretion in Euthyroid Man Under the Influence of Thyroid Hormone and Glucocorticoid Administration*
  387. Inhibition of rat liver iodothyronine deiodinase. Interaction of aurones with the iodothyronine ligand-binding site.
  388. Rat liver iodothyronine monodeiodinase. Evaluation of the iodothyronine ligand-binding site.
  389. Indicator, cosmetic and food dyes interfere with thyroid hormone metabolism
  390. Crystal structure of phlorizin and the iodothyronine deiodinase inhibitory activity of phloretin analogues
  391. Design of Active Site-Directed Iodothyronine Deiodinase Ligands Using TBPA as a Binding Site Model
  392. Design of an active site model of type I iodothyronine deiodinase and development of optimized iodothyronine analogue enzyme ligands
  393. Structure-activity-relationships of ligands of rat liver iodothyronine deiodinase
  394. Phloretin and polyphloretinphosphate (PPP) - a synthetic high molecular weight phosphorylated polymer - inhibit microsomal membrane iodothyronine deiodinase (ITH-D)
  395. Antihormonal Effects of Plant Extracts: Iodothyronine Deiodinase of Rat Liver is Inhibited by Extracts and Secondary Metabolites of Plants
  396. pH-dependency of iodothyronine metabolism in isolated perfused rat liver
  397. A NEW CLASS OF IODOTHYRONINE DEIODINASE INHIBITORS
  398. Subcellular localization of thyroxine-5-deiodinase in rat liver
  399. Conversion of T3 and rT3 to 3,3′-T2: pH dependency
  400. ChemInform Abstract: PREPARATION OF (14C)‐P1,P5‐DI(ADENOSINE)5′‐PENTAPHOSPHATE BY DIRECT REACTION OF (14C)‐ADENOSINE 5′‐DIPHOSPHATE WITH ACTIVATED ADENOSINE 5′‐TRIPHOSPHATE
  401. P1, P5-Bis-(5′-adenosyl)pentaphosphate: Is this Adenylate Kinase Inhibitor Substrate for Mitochondrial Processes?
  402. Darstellung von [14C]‐P1,P5‐Di(adenosin‐5′‐)pentaphosphat durch direkte Umsetzung von [14C]‐Adenosin‐5′‐diphosphat mit aktiviertem Adenosin‐′‐triphosphat
  403. Grundlagen der parakrinen, autokrinen und intrakrinen Regulation endokriner Organe